New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2013
13:53 EDTGSK, SRPTSarepta higher after report of hospitalizations related to GSK drug
Shares of Sarepta Therapeutics (SRPT) are up $2.86, or 9.85%, to $31.89 and the strength is being attributed to a report by TheStreet.com that said patients were hospitalized after being treated with GlaxoSmithKline's (GSK) experimental drug for Duchenne muscular dystrophy. The report adds that Sarepta is scheduled to meet with the FDA this quarter to discuss a possible accelerated approval filing of its own Duchenne muscular dystrophy treatment, eteplirsen.
News For SRPT;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
09:21 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
07:15 EDTGSKAgenus reports GSK ZOE-50 Phase 3 study met primary endpoint
Subscribe for More Information
December 9, 2014
10:23 EDTGSKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTGSKARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:44 EDTGSKAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:37 EDTGSKGlaxoSmithKline downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded GlaxoSmithKline to Underperform citing a lack of pipeline catalysts and its belief the European pharma sector is close to fair value.
December 8, 2014
13:32 EDTGSKEpizyme announces results for PRMT5 inhibitor
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use